Journal article
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
- Abstract:
-
Objective Evaluate long-term guselkumab effectiveness across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-recognised domains/related conditions of psoriatic arthritis (PsA).
Methods Post hoc analyses used data from DISCOVER-2 (NCT03158285) biologic/Janus-kinase inhibitor-naïve participants with active PsA (≥5 swollen/≥5 tender joints, C-reactive protein ≥0.6 mg/dL), randomised (1:1:1) to guselkumab every 4 or 8 we...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 805.6KB, Terms of use)
-
- Publisher copy:
- 10.1136/rmdopen-2023-003977
Authors
Bibliographic Details
- Publisher:
- BMJ Publishing Group
- Journal:
- RMD Open More from this journal
- Volume:
- 10
- Issue:
- 1
- Article number:
- e003977
- Publication date:
- 2024-03-26
- Acceptance date:
- 2024-02-08
- DOI:
- EISSN:
-
2056-5933
Item Description
- Language:
-
English
- Pubs id:
-
1615630
- Local pid:
-
pubs:1615630
- Deposit date:
-
2024-02-09
Terms of use
- Copyright holder:
- Coates et al.
- Copyright date:
- 2024
- Rights statement:
- © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record